A view from the Center


Deloitte's Life Sciences & Health Care Blog

Filter by category or month:

Drug rebates will remain… but so will pressure to reduce drug prices and demonstrate value

by George van Antwerp, managing director, and Joseph M. Coppola, managing director, Life Sciences Commercial and Market Access, Deloitte Consulting LLP

On July 10, the White House abandoned efforts to eliminate safe-harbor protections for drug rebates in Medicare Part D and Medicaid managed care due to concerns that the change would lead to higher premiums for beneficiaries. (For background on this issue, see our previous blogs.) While the rebate issue is now off the table,

Read more

Back to the future: With increased scrutiny over price increases, the fundamentals of organic growth in biopharma are more important than ever

by Cameron McClearn, principal, and Tom Yang, principal, Deloitte Consulting LLP

Price increases. This is arguably the most discussed topic in the biopharmaceutical industry today. In January, biopharmaceutical manufacturers raised list prices on more than 250 products.1 In July, 20 companies increased the list prices for more than 40 prescription drugs by an average of 13 percent.2 But are annual price increases a sustainable mechanism for driving future growth in biopharma?

Read more

Catalysts for change: Meet the life sciences regulator of the future

by Kevin Brault, Federal Health Care Sector Leader, Deloitte & Touche LLP

As technology continues to drive the health sector further ahead, regulators—particularly in life sciences—might need to become more agile so they can foster innovation while continuing to ensure product effectiveness and consumer safety. Regulatory bodies have historically issued rules and required industries to abide by them. But the future of health is being largely dictated by software.

Read more

Sorry for sounding like a broken record…but our industry is nearing a transformational change

by Neal Batra, Principal and Mike DeLone, Principal, Deloitte Consulting LLP

For people who grew up in the 1970s and ’80s, rifling through album racks at the local record store was one of life’s great pleasures. Over the past 20+ years, most of the record-store chains (Tower Records, Sam Goody, Musicland) that once flourished in or near shopping malls across the country—as well as the majority of independent shops—have all but vanished.1 It’s not because these businesses were poorly run.

Read more

Forging a new path to commercialization for cell and gene therapies

by Greg Reh, Vice Chairman, US and Global Life Sciences Leader, Deloitte LLP

Greg Reh comments on the panel discussion from the Financial Times US Pharma and Biotech Summit about the changes needed to face coming innovations in manufacturing, pricing, and reimbursement of personalized therapies. These innovations include direct-to-payer models, mass customization, and valuation of gene therapies and one-time treatments, all of which present unique challenges to pharma companies’ current technology systems.

Read more

Safety first: Technology and analytics could help transform pharmacovigilance

by Kelly Traverso, Life Sciences R&D, Deloitte Consulting LLP

Sometimes a relatively small investment can lead to the development of a product or process that benefits a company, an industry, or even society as a whole. The three-point seat belt, for example, is a simple strap of nylon webbing that protects drivers and passengers from being injured in an accident. This innovation helped to transform safety standards in the automotive industry and has saved millions of lives.

Read more